Stay Notified Of Our Blog Updates

UgenTec opens US sales office

Thomas Beuls | Press Release | UgenTec | 14/06/2018

Hasselt, Belgium & Boston, Massachusetts - UgenTec, a software company focusing on simplifying and automating real-time qPCR diagnostics, today announces it has opened a United States subsidiary sales office. Paul Ventura, a seasoned life science executive, will be spearheading the US sales efforts.

Announcing our partnership with Serosep Ltd.

Thomas Beuls | Press Release | UgenTec | Partnership | 19/04/2018

We're excited to announce today our partnership with Serosep Ltd.,  a leading global manufacturer of molecular solutions for clinical laboratories. In the partnership, we will add the Serosep EntericBio assay range to our platform FastFinder. 

Announcing the Molecular Automation Network & our partnership with Hamilton Robotics

Thomas Beuls | Press Release | UgenTec | Partnership | 10/04/2018

We're excited to announce our brand new initiative in molecular diagnostics: the Molecular Automation Network. This network is a consortium of companies that are currently active in molecular diagnostics & automation. Its purpose is to connect the MDx industry better, enabling more complete solutions and end to end workflows across the globe.

Announcing our $ 9.3 million Series A funding

Thomas Beuls | Funding | Press Release | UgenTec | 29/03/2018

We're excited to announce our series A funding round. Existing and new investors subscribed to the round for a total worth of $9,3 million (€7,5 million). The funds will be used to consolidate our leading position in clinical diagnostics, setting up a US office and expanding to new markets.

UgenTec and MDxHealth sign partnership agreement for software to support interpretation of molecular test results

Thomas Beuls | Press Release | Partnership | 23/01/2018

HERSTAL & HASSELT, BELGIUM – 23/01/18 | UgenTec, an innovative European medical device software company that develops artificially intelligent PCR interpretation software, announced today a partnership agreement with MDxHealth, a multinational healthcare company that uses molecular diagnostics to personalize urological cancer diagnosis and treatment.